Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving ...

The Washington University trial comes as part of a larger platform study, which hopes to understand whether the disease can ...

BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...

Eli Lilly has reported comprehensive outcomes from the Phase III SUMMIT trial of tirzepatide for individuals with heart failure with preserved ejection fraction (HFpEF) and obesity. The double ...

The FDA has approved Eli Lilly’s Omvoh (mirikizumab-mrkz ... Omvoh is the first biologic drug in over 15 years to provide the FDA with two-year Phase III efficacy data at approval. The regulatory ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...